News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
ChartMill Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Protagonist Therapeutics (NASDAQ:PTGX) has received an average "Moderate Buy" rating from eighteen brokerages, with an average 12-month price target of $137.86. The company recently reported strong quarterly earnings and revenue, exceeding consensus estimates, while its shares trade near their 12-month high. Despite recent insider …
Protagonist Therapeutics CEO Dinesh Patel sold 100,000 shares of the company's common stock for approximately $14.9 million on August 10 and 11, 2026. These sales were part of a pre-arranged 10b5-1 trading plan after exercising stock options at $21.58 per share. The transactions occurred …
Protagonist Therapeutics President and CEO Dinesh V. Patel exercised stock options for 100,000 shares at $21.58 each and subsequently sold all 100,000 shares in open-market transactions on August 10-11, 2026. The sales, conducted under a Rule 10b5-1 trading plan, generated approximately $14.89 million in …
Protagonist Therapeutics CEO Dinesh Ph. Patel sold 34,239 shares of company stock for over $5 million on August 11th, reducing his stake by 6.14% while still holding a significant position. This transaction, made under a pre-arranged trading plan, occurred as PTGX shares rose 2.5% …
Protagonist Therapeutics has received FDA approval for ICOTYDE to treat moderate-to-severe plaque psoriasis, reinforcing its "Strong Buy" rating. The company is also advancing rusfertide for polycythemia vera, with an FDA Priority Review decision expected by August 2026, and developing PN-881 for psoriasis. These developments …
Protagonist Therapeutics (NASDAQ:PTGX) recently achieved a new 52-week high of $151.88, closing at $148.29, driven by strong analyst sentiment and exceeding quarterly earnings expectations. The company reported $2.29 EPS against a $2.27 estimate and a significant 3,746.8% year-over-year revenue surge to $213.47 million. Despite …
Silence Therapeutics' (SLN) Phase 2 results for divesiran in polycythemia vera showed stronger activ PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …
An insider at Protagonist Therapeutics (PTGX) has filed to sell 225,000 common shares under Rule 144, with an aggregate market value of $33,583,500. The sale will be executed through J.P. Morgan Securities LLC on Nasdaq and is associated with an option exercise. This filing …
Wedbush has increased its price target for Protagonist Therapeutics (PTGX) to $173 from $118, while maintaining an Outperform rating on the stock. This adjustment reflects a more optimistic outlook from the analyst firm.
Goldman Sachs upgraded Protagonist Therapeutics (PTGX) to a buy rating from neutral, setting a price target of $186. The upgrade is driven by the promising potential of the company's phase 1 oral IL-17 antagonist, PN-881, which is being developed for various autoimmune conditions. This …
Goldman Sachs has upgraded Protagonist Therapeutics (PTGX) to a "Buy" rating from "Neutral" and increased its price target to $186 from $110. The article also notes that Protagonist Therapeutics has an average rating of "Buy" and a mean price target of $159.36 from other …
Wedbush has increased its target price for Protagonist Therapeutics, Inc. to $173, up from the previous $118. The information is provided by Reuters and indicates a significant positive revision in the analyst's outlook for the company's stock.
Truist has raised its price target for Protagonist Therapeutics (NASDAQ: PTGX) from $145 to $170, while maintaining a "Buy" rating on the stock. This adjustment reflects a continued positive outlook from the firm on the biopharmaceutical company. Other analysts, including Goldman Sachs and Wedbush, …
Goldman Sachs upgraded Protagonist Therapeutics (NASDAQ:PTGX) to Buy from Neutral, raising its price target to $186 from $110, citing the potential of its oral IL-17 drug, PN-881. The company recently reported strong Q2 2026 financial results, including significant license and collaboration revenue and a …
Protagonist Therapeutics (PTGX) recently reported a swing to net income of US$162.85 million in Q2 2026, leading to significant share price momentum. Despite a high Price-to-Earnings ratio of 113.8x compared to industry averages, driven by strong future earnings growth forecasts, the company's Discounted Cash …
Wall Street Zen has downgraded Protagonist Therapeutics (NASDAQ:PTGX) from a "strong buy" to a "buy" rating. Despite this, the broader analyst consensus remains a "Moderate Buy" with an average price target of $126.71. The company recently reported strong quarterly earnings, beating estimates with $2.29 …
State Street Corporation has reported a 5.2% passive beneficial ownership stake in Protagonist Therapeutics, Inc., holding 3,321,554 common shares. The filing indicates that State Street exercises shared voting power over 3,157,671 shares and shared dispositive power over all 3,321,554 shares through various investment management …
Protagonist Therapeutics (PTGX) is showing significant upside potential due to notable revisions in its earnings estimates, reflecting growing optimism from analysts. The company's earnings outlook continues to improve, with current-quarter EPS expected to increase by 446.8% and full-year EPS by 280.0%. This positive trend …
Protagonist Therapeutics (PTGX) saw its stock price surge after reporting a significant profit inflection in Q2 2026, with revenue reaching US$213.5 million and basic EPS at US$2.47, a major turnaround from previous losses. This shift is largely attributed to the strong performance of ICOTYDE …
The California State Teachers Retirement System increased its stake in Protagonist Therapeutics (NASDAQ:PTGX) by 22.2% in Q1, now holding 58,677 shares valued at $6.2 million. Despite insider sales totaling $11.5 million in the last 90 days, institutional investors own 98.63% of the company, and …
Protagonist Therapeutics, Inc. (PTGX) has seen its average 12-month price target raised to $152.14 by 14 analysts, up from $148.93. This updated target suggests an 11% potential upside from the August 5 closing price. The consensus rating for PTGX remains "Buy," with 13 analysts …
Protagonist Therapeutics, Inc. (PTGX) announced its Q2 revenue of $213.5 million, surpassing the FactSet estimate of $199.8 million. This report highlights a stronger-than-expected financial performance for the quarter.
Citigroup has raised its price target for Protagonist Therapeutics (NASDAQ:PTGX) to $175 from $130, maintaining a "buy" rating and implying a 19.78% upside. The company recently exceeded quarterly earnings expectations, reporting $2.29 EPS against $2.24 expected, and revenues of $213.47 million. Despite positive analyst …
Protagonist Therapeutics (PTGX) stock has reached an all-time high of $143.43, reflecting strong investor confidence and a 155% return over the past year. The biotech firm, with an $8.83 billion market cap, is projected to see significant revenue growth and profitability by 2026, despite …
Leerink Partners has increased its target price for Protagonist Therapeutics, Inc. to $150.00, up from the previous $110.00. This adjustment reflects an updated outlook from the financial firm regarding the biotechnology company. The information was reported by Reuters.
Barclays has maintained an "Overweight" rating on Protagonist Therapeutics (PTGX), increasing its price target to $153 from $151. Despite this cautious optimism from analysts, Protagonist Therapeutics is considered significantly overvalued with a GF Value of $72.54 against its current price of $144.87, and insider …
Citigroup has raised its target price for Protagonist Therapeutics, Inc. to $175 from $130. This update indicates a significant increase in the analyst's valuation of the company. The article, sourced from Reuters, briefly notes this financial adjustment.
Protagonist Therapeutics, Inc reported significantly increased revenue of $213.48M and diluted EPS of $2.29 for the 2026 quarter, largely due to license and collaboration revenue from a Takeda opt-out payment and a J&J milestone. The company achieved a net income of $162.85M compared to …
Protagonist Therapeutics, Inc. has released its earnings summary for the quarter that concluded on June 30. The report is available on TradingView, sourced from Refinitiv and Reuters.
Search by ticker symbol or company name and select a result to open its chart.